Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize...
Year: 2023
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on...
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies...
BioAdaptives Inc. Announced Today the Signing of a License for Eye Health due to Myopia and Presbyopia; a Patent Valued at US$ 570,000,000
LAS VEGAS, NV, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the signing...
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the...
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway...
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory propertiesSAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma,...
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET...
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023...
Atlas Global Brands to Participate in Benzinga Cannabis Capital Conference
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, March 30, 2023 (GLOBE NEWSWIRE) -- Atlas Global Brands Inc. (“Atlas Global” or...
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.),...
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
Acquired IXINITY® commercial payment and milestone economics from Aptevo TherapeuticsEMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ETLITTLETOWN, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos...
Resolutions from Novozymes A/S’ Extraordinary Shareholders’ Meeting on 30 March 2023
Please read the announcement in PDF Attachment 2023_51_Novozymes_extraordinary_shareholders_meeting_resolutions
Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES...
Combination between Novozymes and Chr. Hansen approved by the Novozymes shareholders
Please read the announcement in PDF Attachment 2023_50_Combination_between_Novozymes_and_Chr._Hansen_approved_by_the_Novozymes_shareholders
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment...
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched...